Therapeutic Focus: <em>Drop</em>ping Some Knowledge
Vizz (aceclidine ophthalmic solution) 1.44%, from Lenz Therapeutics, offers spectacle-free vision and the opportunity to secure patient loyalty.
By
Julie Greenbaum, editor
January 1, 2026
Clinical Scorecard: Therapeutic Focus: Dropping Some Knowledge
At a Glance
Category Detail
Condition Presbyopia Key Mechanisms Pupil-selective miotic action that contracts the iris sphincter muscle, enhancing depth of focus without myopic shift. Target Population Patients with presbyopia seeking spectacle-free vision. Care Setting Ophthalmology practices.
Key Highlights
Vizz (aceclidine ophthalmic solution) 1.44% improves near vision within 30 minutes. Provides functional vision across distance, intermediate, and near ranges. Enhances patient satisfaction and loyalty, leading to increased referrals. Offers a solution for presbyopic patients who wear contact lenses. Minimal side effects such as mild redness or burning upon instillation. Guideline-Based Recommendations
Diagnosis
Assess visual acuity and patient history to confirm presbyopia. Management
Consider Vizz as a treatment option for presbyopia to improve near vision. Monitoring & Follow-up
Monitor patient response to Vizz within 30 minutes of administration. Risks
Inform patients about potential mild side effects like redness or burning. Patient & Prescribing Data
Presbyopic patients, including those who wear contact lenses.
Vizz can be used alongside contact lenses for improved near vision without the need for reading glasses.
Clinical Best Practices
Manage patient expectations regarding potential side effects. Tailor solutions to individual patient needs to enhance satisfaction. Encourage referrals by providing effective treatment options. References
